You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

minimal residual disease in AML patients

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, Adult, Minimal Residual Disease Trial (MRD assessment)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • MRD assessment
  • (no location specified)
Oct 13, 2023

Minimal Residual Disease Trial in Tianjin (QN-030a, Cyclophosphamid, Fludarabine)

Recruiting
  • Minimal Residual Disease
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 3, 2022

AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • chidamide and azacitidine
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Sep 27, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

Recruiting
  • Leukemia, Myeloid, Acute
  • Minimal Residual Disease
    • Chapel Hill, North Carolina
      North Carolina Cancer Hospital (NCCH)
    Feb 2, 2023

    Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,

    Recruiting
    • Acute Myeloid Leukemia in Remission
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 13, 2022

    Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

    Not yet recruiting
    • Hematologic Malignancy
    • +21 more
    • (no location specified)
    Feb 9, 2023

    Acute Myeloid Leukemia Trial in Beijing (DC vaccine)

    Recruiting
    • Acute Myeloid Leukemia
    • DC vaccine
    • Beijing, Beijing, China
      Department of hematology
    Aug 16, 2021

    Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome Trial in Worldwide (AMG 330)

    Terminated
    • Relapsed/Refractory AML
    • +2 more
    • AMG 330
    • Birmingham, Alabama
    • +10 more
    Nov 9, 2022

    Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)

    Recruiting
    • Leukemia
    • +19 more
    • CYNK-001
    • Denver, Colorado
    • +9 more
    Sep 9, 2022

    Microfluidic Assay to Detect Minimal Residual Disease and

    Completed
    • Acute Myeloid Leukemia
      • Chapel Hill, North Carolina
        UNC Lineberger
      Jan 12, 2021

      Acute Myeloid Leukemia in Remission, MDS, Minimal Residual Disease Trial in Germany (Pevonedistat, Azacitidine)

      Active, not recruiting
      • Acute Myeloid Leukemia in Remission
      • +2 more
      • Aachen, Germany
      • +13 more
      Jul 11, 2022

      Minimal Residual Disease Using Multi-omics Approach

      Not yet recruiting
      • Pancreatic Ductal Adenocarcinoma
      • Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
      • Shanghai, China
        Department of Pancreatic and Hepatobiliary Surgery, Fudan Univer
      Nov 29, 2023

      Minimally Residual of Esophageal Cancer 001

      Recruiting
      • Esophageal Carcinoma
      • Minimal Residual Disease
        • Shijiazhuang, Hebei, China
          Fourth Hospital of Hebei Medical University
        Jul 17, 2023

        B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

        Recruiting
        • B-Cell Lymphoblastic Leukemia
        • Acute Lymphoblastic Leukemia
        • Tampa, Florida
          Moffitt Cancer Center
        Nov 28, 2023

        Acute Myeloid Leukemia Trial in Germany (FLYSYN)

        Completed
        • Acute Myeloid Leukemia
        • FLYSYN
        • Tuebingen, Baden-Wuerttemberg, Germany
        • +4 more
        Sep 27, 2021

        GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE

        Enrolling by invitation
        • Pancreatic Adenocarcinoma
        • liquid biopsy
        • Stockholm, Sweden
          Gastrocentrum, KarolinskaUniversity Hospital
        Oct 26, 2023

        Next-generation Sequencing in Pediatric B-ALL Children Patients

        Not yet recruiting
        • Acute Lymphoblastic Leukemia, Pediatric
        • (no location specified)
        Apr 19, 2023

        Acute Myeloid Leukemia (AML) or Minimal Residual Disease (MRD Plus) Trial in Pessac, Paris (Human T Lymphoid Progenitor (HTLP)

        Recruiting
        • Acute Myeloid Leukemia (AML) or Minimal Residual Disease (MRD Plus)
        • Human T Lymphoid Progenitor (HTLP) injection
        • Pessac, France
        • +1 more
        Oct 28, 2021

        Minimal Residual Disease of Acute Myelogenous Leukemia or High

        Recruiting
        • Acute Myeloid Leukemia
        • Myelodysplastic Syndrome
          • Rochester, New York
            University of Rochester Medical Center
          May 3, 2022

          Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

          Not yet recruiting
          • Multiple Myeloma
          • (no location specified)
          Jan 10, 2023

          MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

          Not yet recruiting
          • Multiple Myeloma
          • Minimal Residual Disease
            • (no location specified)
            Nov 1, 2023

            Stage II-III Gastric Cancer Trial in Jinan, Qingdao, Yantai (MRD-guided therapy)

            Recruiting
            • Stage II-III Gastric Cancer
            • MRD-guided therapy
            • Jinan, Shandong, China
            • +4 more
            Nov 27, 2023

            Danish Assessment of Minimal Residual Disease by Liquid Biopsies

            Recruiting
            • Colorectal Neoplasms
            • +5 more
              • Copenhagen, Capital Region Of Denmark, Denmark
              • +8 more
              Oct 13, 2023

              Using Mass Spectrometry Detecting Minimal Residual Disease in

              Recruiting
              • Multiple Myeloma
                • Tianjin, China
                  InsituteHBDH
                Sep 8, 2022